NEW ORLEANS, Nov. 04, 2017 (GLOBE NEWSWIRE) — Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to people with kidney disease, today presented new real world data from a large dialysis provider that showed Auryxia® (ferric citrate) tablets, when dosed as a phosphate binder, reduced erythropoiesis-stimulating agent (ESA) and intravenous iron (IV iron) use, while maintaining hemoglobin levels in patients on dialysis.